{
    "info": {
        "nct_id": "NCT04089449",
        "official_title": "A Phase 1, Open-Label, Multicenter, Dose Escalation and Expansion Study of PRT811 in Subjects With Advanced Solid Tumors, CNS Lymphoma, and Recurrent High-Grade Gliomas",
        "inclusion_criteria": "* Malignancies that are refractory to or intolerant of established therapies known to provide clinical benefit for the malignancy in question, or in the opinion of the Investigator, not be a candidate for such therapies\n* Subjects must have recovered from the effects of any prior investigational system therapies\n* For subjects with recurrent high-grade glioma or GBM, must have biopsy proven evidence (WHO Grade III or IV) and received external bean fractionated radiotherapy and at least 2 cycles of adjuvant temozolomide chemotherapy. Mutant Glioma must comply with biomarker defined enrollment criterias.\n* For biomarker-selected solid tumors: must meet enrollment criteria\n* Eastern Cooperative Oncology Group (ECOG) Performance Score of 0 or 1\n* Adequate organ function (bone marrow, hepatic, renal, cardiovascular)\n* Female subjects of childbearing potential must have a negative pregnancy test within 7 days of the start of treatment and must agree to use an effective method of contraception during the trial\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "* Untreated concurrent malignancies or malignancies that have been in complete remission for less than one year\n* Treatment with strong inhibitors of CYP3A4 for which there are no therapeutic substitutions\n* Inflammatory disorders of the gastrointestinal tract, or subjects with GI malabsorption\n* HIV positive; known active hepatitis B or C\n* Known hypersensitivity to any of the components of PRT811",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "* Eastern Cooperative Oncology Group (ECOG) Performance Score of 0 or 1",
            "criterions": [
                {
                    "exact_snippets": "Eastern Cooperative Oncology Group (ECOG) Performance Score of 0 or 1",
                    "criterion": "ECOG Performance Score",
                    "requirements": [
                        {
                            "requirement_type": "score",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": ""
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 1,
                                        "unit": ""
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Subjects must have recovered from the effects of any prior investigational system therapies",
            "criterions": [
                {
                    "exact_snippets": "Subjects must have recovered from the effects of any prior investigational system therapies",
                    "criterion": "recovery from effects of prior investigational systemic therapies",
                    "requirements": [
                        {
                            "requirement_type": "recovery",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "Years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* For biomarker-selected solid tumors: must meet enrollment criteria",
            "criterions": [
                {
                    "exact_snippets": "For biomarker-selected solid tumors",
                    "criterion": "biomarker-selected solid tumor",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "must meet enrollment criteria",
                    "criterion": "enrollment criteria",
                    "requirements": [
                        {
                            "requirement_type": "meets criteria",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* For subjects with recurrent high-grade glioma or GBM, must have biopsy proven evidence (WHO Grade III or IV) and received external bean fractionated radiotherapy and at least 2 cycles of adjuvant temozolomide chemotherapy. Mutant Glioma must comply with biomarker defined enrollment criterias.",
            "criterions": [
                {
                    "exact_snippets": "recurrent high-grade glioma or GBM",
                    "criterion": "diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": [
                                "recurrent high-grade glioma",
                                "GBM"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "biopsy proven evidence (WHO Grade III or IV)",
                    "criterion": "tumor grade",
                    "requirements": [
                        {
                            "requirement_type": "confirmation method",
                            "expected_value": "biopsy proven"
                        },
                        {
                            "requirement_type": "grade",
                            "expected_value": [
                                "WHO Grade III",
                                "WHO Grade IV"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "received external bean fractionated radiotherapy",
                    "criterion": "external beam fractionated radiotherapy",
                    "requirements": [
                        {
                            "requirement_type": "treatment received",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "at least 2 cycles of adjuvant temozolomide chemotherapy",
                    "criterion": "adjuvant temozolomide chemotherapy",
                    "requirements": [
                        {
                            "requirement_type": "number of cycles",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "cycles"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Mutant Glioma must comply with biomarker defined enrollment criterias",
                    "criterion": "biomarker criteria for mutant glioma",
                    "requirements": [
                        {
                            "requirement_type": "compliance",
                            "expected_value": "biomarker defined enrollment criteria"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Female subjects of childbearing potential must have a negative pregnancy test within 7 days of the start of treatment and must agree to use an effective method of contraception during the trial",
            "criterions": [
                {
                    "exact_snippets": "Female subjects of childbearing potential",
                    "criterion": "sex and childbearing potential",
                    "requirements": [
                        {
                            "requirement_type": "sex",
                            "expected_value": "female"
                        },
                        {
                            "requirement_type": "childbearing potential",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "must have a negative pregnancy test within 7 days of the start of treatment",
                    "criterion": "pregnancy test",
                    "requirements": [
                        {
                            "requirement_type": "result",
                            "expected_value": "negative"
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "within 7 days of the start of treatment"
                        }
                    ]
                },
                {
                    "exact_snippets": "must agree to use an effective method of contraception during the trial",
                    "criterion": "contraception use",
                    "requirements": [
                        {
                            "requirement_type": "agreement to use",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "method effectiveness",
                            "expected_value": "effective"
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": "during the trial"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Malignancies that are refractory to or intolerant of established therapies known to provide clinical benefit for the malignancy in question, or in the opinion of the Investigator, not be a candidate for such therapies",
            "criterions": [
                {
                    "exact_snippets": "Malignancies that are refractory to ... established therapies known to provide clinical benefit for the malignancy in question",
                    "criterion": "malignancy response to established therapies",
                    "requirements": [
                        {
                            "requirement_type": "refractoriness",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Malignancies that are ... intolerant of established therapies known to provide clinical benefit for the malignancy in question",
                    "criterion": "malignancy response to established therapies",
                    "requirements": [
                        {
                            "requirement_type": "intolerance",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "in the opinion of the Investigator, not be a candidate for such therapies",
                    "criterion": "eligibility for established therapies (per Investigator)",
                    "requirements": [
                        {
                            "requirement_type": "candidate status",
                            "expected_value": "not a candidate (per Investigator opinion)"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Adequate organ function (bone marrow, hepatic, renal, cardiovascular)",
            "criterions": [
                {
                    "exact_snippets": "Adequate organ function (bone marrow",
                    "criterion": "bone marrow function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Adequate organ function ... hepatic",
                    "criterion": "hepatic function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Adequate organ function ... renal",
                    "criterion": "renal function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Adequate organ function ... cardiovascular",
                    "criterion": "cardiovascular function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Inflammatory disorders of the gastrointestinal tract, or subjects with GI malabsorption",
            "criterions": [
                {
                    "exact_snippets": "Inflammatory disorders of the gastrointestinal tract",
                    "criterion": "inflammatory disorders of the gastrointestinal tract",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "subjects with GI malabsorption",
                    "criterion": "GI malabsorption",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Treatment with strong inhibitors of CYP3A4 for which there are no therapeutic substitutions",
            "criterions": [
                {
                    "exact_snippets": "Treatment with strong inhibitors of CYP3A4",
                    "criterion": "treatment with strong CYP3A4 inhibitors",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "for which there are no therapeutic substitutions",
                    "criterion": "availability of therapeutic substitutions for strong CYP3A4 inhibitors",
                    "requirements": [
                        {
                            "requirement_type": "availability",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known hypersensitivity to any of the components of PRT811",
            "criterions": [
                {
                    "exact_snippets": "Known hypersensitivity to any of the components of PRT811",
                    "criterion": "hypersensitivity to components of PRT811",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Untreated concurrent malignancies or malignancies that have been in complete remission for less than one year",
            "criterions": [
                {
                    "exact_snippets": "Untreated concurrent malignancies",
                    "criterion": "concurrent malignancies",
                    "requirements": [
                        {
                            "requirement_type": "treatment status",
                            "expected_value": "untreated"
                        }
                    ]
                },
                {
                    "exact_snippets": "malignancies that have been in complete remission for less than one year",
                    "criterion": "malignancies in complete remission",
                    "requirements": [
                        {
                            "requirement_type": "remission duration",
                            "expected_value": {
                                "operator": "<",
                                "value": 1,
                                "unit": "year"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [],
    "failed_exclusion": [
        {
            "line": "* HIV positive; known active hepatitis B or C",
            "criterions": [
                {
                    "exact_snippets": "HIV positive",
                    "criterion": "HIV infection",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "known active hepatitis B",
                    "criterion": "active hepatitis B infection",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "known active hepatitis C",
                    "criterion": "active hepatitis C infection",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "failed_miscellaneous": []
}